After eight weeks, rasagiline significantly improved sleep maintenance (+16.3%, p = 0.024), showed a trend toward better sleep efficiency (+12.1%, p = 0.097), and significantly reduced wake time after sleep onset (WASO) ( p = 0.048).
While there were no significant changes in the PDSS scores, indicating no substantial improvement in subjective sleep quality, there was a notable trend in improvement in depression scores as measured by the Beck Depression Inventory-II (BDI-II) within the rasagiline group ( p = 0.15) and a significant difference between groups ( p = 0.018).